|
Short Courses | Day 1 | Day 2 | Day 3 | Download Brochure Friday, February 5
TRANSLATIONAL INFORMATICS- 8:30 AM Chairperson's Opening Remarks Pearl S. Huang, Ph.D., Integrator, Oncology Franchise, Research & Early Development, Merck & Co. 8:35 Implementing a Translational Biomarker Strategy to Reduce Attrition in Drug Development Irina Antonijevic, M.D., Ph.D., Director, Translational Research, Biological Research, Lundbeck Research, Inc. USA Early efforts towards the discovery of molecular biomarkers for CNS disorders are encouraging. However, confirmation, and ultimately validation of such biomarkers is dependent on state-of-the-art bioinformatics analyses as well as assay development. These prerequisites will ensure identification of biomarkers that are reproducible and hence of clinical relevance. 9:05 High Content Mining of Disease Biomarkers Jake Chen, Ph.D., Assistant Professor, Informatics & Computer Science, Indiana University School of Informatics; Director, Indiana Center for Systems Biology and Personalized Medicine, Indiana University-Purdue University Indianapolis; Founder, MedeoLinx, Inc. To facilitate the interpretation of raw Omics data into detailed disease-specific knowledge of candidate biomarkers, we developed a "high-content biomarker mining" software system. The system can help manage and correlate molecular functions, molecular connectivity, biological pathways, and literature information. Its application into the current biomarker development process will help improve the success rate and quality of candidate biomarkers. 9:35 Single Molecule Real Time Biology: New technologies Enabling a More Complete Characterization of Disease Biology Eric Schadt, Ph.D., Chief Scientific Officer, Pacific Biosciences While there has been an explosion of technologies that enable more comprehensive characterizations of complex biological processes like common human diseases, we are still unable to glimpse a large enough fraction of the biology of these systems to build models that are predictive enough to achieve clinical utility. However, with a new wave of technologies on the horizon, providing for the capability to examine the activity of single molecules real time, we will soon be capable of generating the right scale and diversity of data (DNA sequence, RNA sequence, real time monitoring of mRNA translation, full characterizations of base modifications in genomes and transcriptomes) at low cost to dramatically enhance the construction of models for common human diseases that achieve clinical utility. I will cover the single molecule real time (SMRT) technologies from Pacific Biosciences and how these technologies will revolutionize our ability to characterize living systems, and then present a number of integrative biology approaches to taking the types of data SMRT technologies will generate to get at predictive models of disease that can be used to drive the identification and validation of drug targets and biomarkers.
10:20 Coffee Break 11:00 Profiling Patients to Drive Biomarker Development N. R. Nirmala, Ph.D., Director, Biomarker Analysis and Informatics Unit, Translational Sciences, Novartis Institutes of Biomedical Research Gene expression profiling is one of the key ways in which a genome-wide view of a patient's response to drug treatment can be obtained. Such a molecular level view can provide strategies for customized therapies in many contexts. In this talk, the opportunities and challenges that this technology presents will be discussed with a couple of case studies. Extension of this approach to other technologies will also be presented in the context of biomarker development. 11:30 Panel: Informatics at R&D Interphases Moderator: Pearl S. Huang, Ph.D., Integrator, Oncology Franchise, Research & Early Development, Merck & Co.
12:00 PM Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
INTEGRATED GENOMIC, BIOLOGY, AND IMAGE DATA 1:00 Chairperson's Remarks Ajay Shah, Ph.D., MBA, PMP, Director, Research Informatics, Elan Pharmaceuticals, Inc. 1:05 Image Analysis Considerations for Pre-clinical, in vivo Medical Imaging Matt Silva, Head, Imaging Sciences, Millennium, The Takeda Oncology Company With the expanding role of preclinical and translational imaging in drug research, it is necessary to consider not only study design and imaging modality but also visualization and image quantification. This presentation will review the role of imaging technologies and show examples of experiments and image analysis procedures, including kinetic analysis of dynamic contrast-enhanced MRI and bone topology analysis from 3D CT data. 1:35 RISe Prowler: A Semantic Web Approach to Integrating External and In-house Biology and Chemistry Information Ajay Shah, Ph.D., MBA, PMP, Director, Research Informatics, Elan Pharmaceuticals, Inc. Contextual understanding and analysis of research data is a challenging task for conventional data integration techniques. RISe (Research Informatics System at elan) Prowler, a hybrid between collaborative editing and data mining systems, utilizes semantic networks to autonomously integrate external data with in-house, annotated experimental biology and chemistry data in a meaningful way. 2:05 Development of a Registration System for Biologics in a Collaborative Special Interest Group Jeremy Packer, Ph.D., Head, Bioinformatics, Abbott 2:35 Development of Combination Therapies for Multiple Sclerosis Using Systems Level Informatics Frederic S. Young, Ph.D., Chief Scientist, Vicus Therapeutics We start with a multilevel systems physiology model that combines metabolomic analysis with integrated physiological analysis. The model is used to define a set of systems informatic features of ontogeny, phylogeny, homeostasis, and repair that distinguishes the disease state from homeostasis. We describe our use of this systems informatic signature as an algorithm for the development of combination therapies for multiple sclerosis. 3:05 Close of Conference
Short Courses | Day 1 | Day 2 | Day 3 | Download Brochure |
|
|
 |